Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.
AnaBios
AnaBios aims to establish the safety and efficacy of novel compounds through its advanced, human-focused translational technologies, including superior quality human tissue samples and functional assays focused, as well as human primary cells through its subsidiary Cell Systems.
BiomimX
BiomimX develops the next generation of beating organs-on-chips. uBeat® Platforms and connected hardware provide 3D miniaturized constructs with a tunable mechanical stimulation to model human organs’ function and diseases. uBeat® products and customized drug screening services are available.
Aracari Bio
Aracari’s vascularized micro-organ and tumor models incorporate perfused human vasculature for the physiologic delivery of nutrients, drugs and immune cells to multiple tissue and tumor types. These powerful next-generation tools are advancing discovery in immuno-oncology and drug development.
Hesperos Inc.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
Curi Bio
Curi’s suite of human iPSC-derived products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.
MIMETAS
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.